Market revenue in 2021 | USD 8.4 million |
Market revenue in 2030 | USD 39.4 million |
Growth rate | 18.8% (CAGR from 2021 to 2030) |
Largest segment | Serum biomarkers |
Fastest growing segment | Hepatic Fibrosis Biomarkers |
Historical data | 2018 - 2020 |
Base year | 2021 |
Forecast period | 2022 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Serum Biomarkers, Hepatic Fibrosis Biomarkers, Apoptosis Biomarkers, Oxidative Stress Biomarkers |
Key market players worldwide | Genfit SA, Siemens AG, Quest Diagnostics Inc, AstraZeneca PLC, Meridian Bioscience, Labcorp Holdings Inc, Pfizer Inc, Bristol-Myers Squibb Co |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to non-alcoholic steatohepatitis biomarkers market will help companies and investors design strategic landscapes.
Serum biomarkers was the largest segment with a revenue share of 33.33% in 2021. Horizon Databook has segmented the Mexico non-alcoholic steatohepatitis biomarkers market based on serum biomarkers, hepatic fibrosis biomarkers, apoptosis biomarkers, oxidative stress biomarkers covering the revenue growth of each sub-segment from 2018 to 2030.
With a prevalence rate of 42.54% among NAFLD patients, the link between NAFLD and metabolic syndrome is well-established. Mexico has a relatively high (41%) reported prevalence of metabolic syndrome. In addition to the prevalence rate of 36.1% in the adult population, Mexico is among the countries with the highest prevalence of obesity in the world.
The prevalence of NAFLD is relatively high worldwide, but Mexicans and other people of Hispanic ancestry are disproportionately affected. The importance of screening patients with metabolic syndrome for NAFLD should be emphasized in countries with high prevalence and inadequate healthcare systems to avoid complications & lessen the disease burden.
For the purpose of diagnosing, noninvasive diagnostics, such as serum biomarkers (including the Fatty Liver Index [FLI], Hepatic Steatosis Index [HSI], and SteatoTest) employed as screening techniques to identify people with NASH.
Horizon Databook provides a detailed overview of country-level data and insights on the Mexico non-alcoholic steatohepatitis biomarkers market , including forecasts for subscribers. This country databook contains high-level insights into Mexico non-alcoholic steatohepatitis biomarkers market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account